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Abstract
Background: Hydroxyurea (HU) is an immunomodulatory agent that has been documented to
enhance the antiretroviral activity of nucleoside reverse transcriptase inhibitors, such as abacavir
(ABC) and didanosine (ddI), and would be expected to improve virologic efficacy.
Methods:  A 48-week, phase IV, multicenter, open-label, proof-of-concept clinical trial was
conducted to evaluate second-line, protease inhibitor (PI)-sparing therapy with ABC/efavirenz
(EFV)/ddI plus HU or without HU in HIV-infected subjects failing to achieve HIV-1 RNA ≤  400
copies/mL after ≥  16 weeks of treatment with lamivudine/zidovudine or lamivudine/stavudine, plus
1 or 2 PIs. Subjects were assigned to ABC (300 mg twice daily)/ EFV (600 mg once daily)/ ddI (400
mg once daily) plus HU (500 mg twice daily) (n = 30) or this regimen without HU (n = 24).
Results: Baseline mean HIV-1 RNA was 3.86 log10 copies/mL and CD4+ cell count was 345 cells/
mm3. A similar percentage of subjects in the non-HU arm (58%) and HU arm (53%) completed the
study. Intent-to-treat: missing = failure analysis showed no differences in proportions of subjects in
the non-HU and HU arms achieving undetectable plasma HIV-1 RNA levels at week 24 (<400
copies/mL: 58% [14/24] vs 57% [17/30], P = 0.899; <50 copies/mL (50% [12/24] vs 47% [14/30], P
= 0.780). Median change from baseline in CD4+ cell count in the non-HU and HU arms at week
48 was +114 cells/mm3 and -63 cells/mm3 (P = 0.007), respectively. Both regimens were generally
well tolerated, although more subjects in the HU arm withdrew prematurely from the study due
to adverse events (23% vs 4%). Four cases of possible ABC-related hypersensitivity were observed.
Conclusion: ABC/EFV/ddI was an effective and well-tolerated second-line regimen for nucleoside/
PI-experienced HIV-infected subjects. The addition of HU blunted the CD4+ cell response, did not
appear to enhance antiviral activity, and resulted in more treatment-limiting adverse events.
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Background
Combination antiretroviral therapy containing protease
inhibitors (PIs) has contributed substantially towards
delaying progression of HIV infection and decreasing
morbidity and mortality [1,2]. However, PI-based regi-
mens require strict adherence to ensure efficacy, and many
of these regimens incur a high pill burden, complex dos-
ing schedules, numerous drug interactions, and metabolic
complications including lipodystrophy, hyperlipidemia,
and elevated glucose levels. A high rate of virologic failure
has been observed with PI-containing regimens in clinical
practice [3]. In view of this, PI-sparing regimens using
nucleoside reverse transcriptase inhibitors (NRTIs) and
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
are attractive for initial and rescue use.
Studies in which the NRTI abacavir (ABC) was substituted
for a PI have shown maintenance of virologic suppression
and CD4+ cell elevation, with reduction in plasma lipid
levels [4-7]. Substitution of the once-daily NNRTI efa-
virenz (EFV) for PIs has also allowed simplification of
therapy with maintenance of virologic suppression [8].
Hirschel et al [9] have shown that when patients are
switched from PIs to EFV they experience less virologic
failure over a 1-year follow-up period than non-switchers.
These results support the use of ABC and EFV in PI-sparing
regimens.
Hydroxyurea (HU) is an immunomodulatory agent that
depletes intracellular deoxynucleotides by inhibiting ribo-
nucleotide reductase, thereby enhancing the antiretroviral
activity of NRTIs and possibly accelerating intracellular
phosphorylation [10,11]. Synergy has been shown in vitro
between HU and didanosine (ddI) [10], and in vivo
(murine AIDS model) between HU and ABC [12]. Regi-
mens employing HU 500 to 1000 mg daily in combina-
tion with ddI have been reported to produce marked
virologic suppression for up to 2 years [13-23]. Combina-
tions of HU with ABC or EFV have also shown promise as
treatment options for antiretroviral-experienced subjects
[23,24]. However, to date, limited data have been pre-
sented on the therapeutic outcome in HIV-infected sub-
jects treated with both EFV and ABC in HU-containing
regimens [24]. The objective of this proof-of-concept
study (NZTA4008) was to evaluate the long-term efficacy,
safety, and tolerability of second-line therapy with ABC,
EFV, ddI, with or without HU, in subjects who had failed
their initial antiretroviral regimens.
Methods
Subjects
Male or female subjects 13 years of age or older were eli-
gible for enrollment in the study if they had a screening
plasma HIV-1 RNA value between 400 and 100,000 cop-
ies/mL, a CD4+ cell count ≥  100 cells/mm3, had experi-
enced virologic failure (HIV-1 RNA ≥  400 copies/mL) after
at least 16 weeks of initial antiretroviral therapy with 1 or
2 PIs with lamivudine and either zidovudine or stavudine,
and had not previously received treatment with non-nucl-
eoside reverse transcriptase inhibitors (NNRTIs), ABC, or
ddI. Subjects were eligible if they had a hemoglobin level
>9.0 g/dL (for women) or >10.0 g/dL (for men), a neu-
trophil count >1,000 cells/mm3, a platelet count >75,000
cells/mm3, an estimated creatinine clearance >50 mL/
min, a serum lipase < the upper limit of normal, a serum
pancreatic amylase level <1.5 times the upper limit of nor-
mal, and levels of hepatic aminotransferases < 5 times the
upper limit of normal within 2 weeks prior to the baseline
visit. Subjects were not eligible for enrollment if they had
been on non-suppressive initial antiretroviral therapy for
>1.5 years, were pregnant or breastfeeding, were receiving
immunomodulating agents, an immunotherapeutic vac-
cine, or cytotoxic chemotherapeutic agents within 8 weeks
before study start, had a history of pancreatitis or periph-
eral neuropathy within 2 months before study start or had
been diagnosed with acute hepatitis within 6 months
before study start.
Study design
This was a Phase IV, randomized, open-label, proof-of-
concept clinical trial that was conducted at 17 study sites
in the United States between September 2, 1999 and April
27, 2001. The study protocol was approved by the institu-
tional review boards at each study site, and all subjects
provided written informed consent prior to their partici-
pation. Subjects were randomly assigned to receive one of
two treatment regimens: ABC 300 mg twice daily, EFV 600
mg once daily, and ddI 400 mg once daily (the non-HU
arm); or the ABC/EFV/ddI regimen with HU 500 mg twice
daily (the HU arm). This study was planned for 48 weeks,
but it concluded after the last subject completed 24 weeks
of treatment because accrual was very slow due to the
highly selective population sought. In the HU treatment
arm, subjects were randomly assigned to start HU either at
baseline or at week 8 in order to investigate whether
delaying HU could prevent cytopenia and a decrease in
CD4+ count.
ABC was supplied as 300-mg tablets of Ziagen® (Glaxo
Wellcome, Research Triangle Park, NC), EFV as 200-mg
capsules of Sustiva® (DuPont Pharmaceuticals, Wilming-
ton, Delaware), ddI as non-enterically-coated 100-mg,
150-mg, and 200-mg tablets of Videx®  (Bristol-Myers
Squibb, Princeton, New Jersey), and HU as 200-mg, 300-
mg, and 500-mg capsules of Droxia®  (Bristol-Myers
Squibb, Princeton, New Jersey). Doses of ddI were admin-
istered at least 30 minutes before a meal or 2 hours after a
meal or snack. The once-daily dose of EFV was adminis-
tered either in the morning or evening, with or withoutBMC Infectious Diseases 2005, 5:23 http://www.biomedcentral.com/1471-2334/5/23
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food. ABC and HU did not have specific dosing require-
ments regarding timing of doses with respect to meals.
Study procedures
Subjects were evaluated at screening, baseline (day 1), and
at weeks 4, 8, 16, 24, 32, 36, 40, and 48. Subjects were
evaluated upon premature discontinuation of the study
and at 4 weeks post-study discontinuation. For subjects
randomized to receive HU beginning at week 8, an addi-
tional study visit was scheduled at week 12 to perform
safety evaluations. Plasma samples were collected at the
study visits for virology, immunology, hematology, and
clinical chemistry assessments that were performed by a
central laboratory (Consolidated Laboratory Services, Van
Nuys, California). Plasma HIV-1 RNA levels were assessed
in blood samples at screening and at all study visits using
both the Roche AMPLICOR PCR Standard 1.0 assay
(lower limit of quantitation [LLOQ] 400 copies/mL) and
the Roche PCR assay Amplicor HIV-1 MONITOR Ultra-
Sensitive Version 1.0 (LLOQ 50 copies/mL) (both assays
from Roche Diagnostics, Branchburg, New Jersey). CD4+
cell counts were determined by flow cytometry. Urinalysis
was performed at baseline and at weeks 4, 12, 16, 24, and
48.
Clinical adverse events and laboratory abnormalities were
assessed and graded according to the standardized AIDS
Clinical Trials Group (ACTG) toxicity grading scales wher-
ever possible (grade 1 or mild to grade 4 or severe). In
cases of suspected HU-related Grade 2 or higher hemato-
logic toxicities, hyperamylasemia, or neuropathy, HU was
discontinued until the toxicity returned to equal to or less
than Grade 2. HU was restarted at a reduced dose and
could be subsequently increased to full dose. If amylase
levels did not decrease following interruption of ddI, all
study medications were to be interrupted. Persistent,
recurrent, or Grade 3 or higher hematologic toxicities,
hyperamylasemia, or neuropathy required permanent dis-
continuation of HU. Doses of ddI could be replaced with
an alternate NRTI. If pancreatitis was diagnosed, all study
drugs were to be permanently discontinued and the sub-
ject discontinued from the study, with or without elevated
amylase levels. If a subject presented with symptoms con-
sistent with a possible ABC-related hypersensitivity reac-
tion, including fever, skin rash, fatigue, and
gastrointestinal symptoms such as nausea, vomiting,
diarrhea, or abdominal pain, therapy with ABC was per-
manently discontinued.
Study endpoints
The primary efficacy endpoint was the proportion of sub-
jects achieving plasma HIV-1 RNA levels <400 copies/mL
at weeks 24 and 48. Secondary efficacy endpoints assessed
at weeks 24 and 48 included the proportion of subjects
achieving plasma HIV-1 RNA <50 copies/mL, change
from baseline in HIV-1 RNA and CD4+ cell count, and
proportion of subjects with at least a 50-cell increase in
CD4+ cell count. During the 48-week study, assessments
were made of the time to virologic failure and time to
treatment failure. Virologic failure was defined by any of
the following: HIV-1 RNA >400 copies/mL by week 24 of
randomized treatment or repeated detection (>400 cop-
ies/mL) after initial suppression to undetectable levels
(<400 copies/mL) or a 3-fold or greater increase in plasma
HIV-1 RNA level from the nadir at week 8 or later not
attributable to intercurrent infection or vaccination. Treat-
ment failure was defined by one or more of the following:
virologic failure, toxicity or other treatment-related with-
drawal, or clinical disease progression (from CDC Catego-
ries A or B to Category C or death, or progression from
Category C to death).
Statistical analysis
Subjects were randomly allocated to the HU and non-HU
arms. Within the HU arm, subjects were randomized
either to treatment with HU starting at study baseline or
to HU starting at 8 weeks post-baseline. Randomization
was stratified by screening HIV-1 RNA (<10,000 copies/
mL and ≥  10,000 copies/mL). The total number of sub-
jects originally planned for this study was 150 (80 in the
HU arm [40 starting HU at baseline and 40 at 8 weeks])
and 70 in the non-HU arm. However, very slow enroll-
ment necessitated participation by fewer subjects. The
proportions of subjects achieving HIV-1 RNA <400 cop-
ies/mL and <50 copies/mL at week 24 was calculated
using an intent-to-treat: missing = failure (ITT: M=F) anal-
ysis. This analysis, which included all randomized sub-
jects, regarded as a treatment failure any subject with
missing values or who did not initiate treatment, changed
treatment, or prematurely discontinued randomized treat-
ment for any reason. The ITT: M=F analysis was not per-
formed at week 48 because of potential bias due to early
termination of the study after the last subject completed
24 weeks. An ITT: observed analysis was performed at
both week 24 and week 48, which included all data from
subjects seen at each specific visit. Comparisons of pro-
portions were made using the Cochran Mantel Haenzel
test. Change from baseline and average area under the
curve minus baseline (AAUCMB) in HIV-1 RNA (log10
copies/mL) and change from baseline CD4+ cell count
were analyzed using the two-sample t-test and Wilcoxon
sum rank test, respectively. Time to virologic failure and
time to treatment failure were analyzed using the Kaplan-
Meier method and compared between the treatment arms
using the log-rank test. The study was not powered to
show statistical differences between the treatment arms.
Differences were deemed statistically significant if the P-
value was <0.05.BMC Infectious Diseases 2005, 5:23 http://www.biomedcentral.com/1471-2334/5/23
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Results
Baseline characteristics and subject disposition
Baseline demographic and disease characteristics were
similar between the treatment arms (Table 1). Most of the
subjects (≥  87%) were male, and approximately one-half
were Caucasian. Baseline median HIV-1 RNA in the non-
HU (n = 24) and HU arms (n = 30) was 3.93 and 3.90
log10  copies/mL, respectively, and median CD4+ cell
counts were 291 and 326 cells/mm3, respectively. A
higher percentage classified CDC Category B was included
Table 1: Baseline demographics and disease characteristics
Characteristic ABC/EFV/ddI (N = 24) ABC/EFV/ddI/HU (N = 30)
Age, years
Mean ± SD 39.5 ± 7.8 38.1 ± 8.4
Median (Range) 37 (29–62) 37 (26–59)
Gender, n (%)
Male 21 (88) 26 (87)
Female 3 (13) 4 (13)
Race, n (%)
Caucasian 13 (54) 16 (53)
African American 8 (33) 4 (13)
Hispanic 2 (8) 7 (23)
Other 1 (4) 3 (10)
CDC classification, n (%)
Category A 9 (38) 19 (63)
Category B 10 (42) 5 (17)
Category C 5 (21) 6 (20)
HIV-1 RNA, log10 copies/mL
Mean ± SD 3.86 ± 0.55 3.86 ± 0.67
Median (Range) 3.93 (2.86–4.73) 3.90 (2.73–4.82)
CD4 cell count, cells/mm3
Mean ± SD 345 ± 192 346 ± 167
Median (Range) 291 (67–805) 326 (53–794)
Prior antiretroviral treatment, n (%)
NRTIs 24 (100) 29 (97)
Lamivudine 16 (67) 19 (63)
Stavudine 11 (46) 18 (60)
Lamivudine/zidovudine combination 
tablet
10 (42) 10 (33)
Zidovudine 5 (21) 4 (13)
Zalcitabine 0 1 (3)
PIs 22 (92) 26 (87)
Nelfinavir mesylate 10 (42) 17 (57)
Indinavir sulfate 7 (29) 7 (23)
Saquinavir 3 (13) 2 (7)
Ritonavir 1 (4) 2 (7)
Lopinavir + ritonavir 1 (4) 1 (3)
Amprenavir 1 (4) 0
Premature withdrawal from study, n (%) 10 (42) 14 (47)
Adverse eventa 1 (4) 7 (23)
Consent withdrawn 2 (8) 0
Protocol-defined virologic failure 5 (21) 1 (3)
Lost to follow-up 1 (4) 3 (10)
Protocol violation 0 1 (3)
Other 1 (4) 2 (7)
Note: ABC, abacavir; ddI, didanosine; EFV, efavirenz; HU, hydroxyurea; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; 
SD, standard deviation.
aAdverse events that led to premature study withdrawal in the HU arm were diarrhea, dizziness, headaches, vomiting, rash on chest, insomnia (1 
patient); pancreatitis (1); decrease in concentration, exacerbation of depression, nightmares (1); fatigue (1); flushing, fatigue, vomiting, nausea, 
palpitations (1); dizziness, incoherence (1); and possible ABC-related hypersensitivity reaction (1). The one patient in the non-HU arm who 
withdrew prematurely from the study did so because of fatal asphyxia, which was not considered related to drug treatment.BMC Infectious Diseases 2005, 5:23 http://www.biomedcentral.com/1471-2334/5/23
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in the non-HU arm (42% vs 17%), and a higher percent-
age classified CDC Category A in the HU arm (63% vs
38%); one-fifth of the subjects in each treatment arm were
Category C. Prior to the study, the most frequently used
NRTIs in each arm had been lamivudine, d4T, and the
lamivudine 150 mg/zidovudine 300 mg combination tab-
let (Combivir®, GlaxoSmithKline, Research Triangle Park,
North Carolina), and the most frequently used PIs had
been nelfinavir mesylate and indinavir sulfate.
Of the subjects in the HU arm, 17 started HU at baseline
and 13 at week 8. A similar percentage of subjects in the
non-HU arm (58% [14/24]) and HU arm (53% [16/30])
completed the study. The reasons for premature with-
drawal from the study are given in Table 1. A greater pro-
portion of subjects in the HU arm withdrew prematurely
due to adverse events (23% vs 4%), whereas a greater pro-
portion in the non-HU arm withdrew due to protocol-
defined virologic failure.
Virologic response
At week 24, the proportion of subjects in the non-HU and
HU treatment arms who achieved HIV-1 RNA <400 cop-
ies/mL was not significantly different, according to the
ITT: M=F analysis (58% [14/24] and 57% [17/30], respec-
tively; P = 0.899, Fig. 1) and ITT: observed analysis (67%
[14/21] and 89% [17/19], respectively; P = 0.081, Fig. 2).
Differences also were not observed at week 48, although
the proportion of subjects with HIV-1 RNA <400 copies/
mL tended to be higher in the non-HU arm in the ITT:
observed analysis (91% [10/11] and 80% [8/10],
respectively; P = 0.512).
Results with the 50-copy/mL assay paralleled those with
the 400-copy/mL assay. At week 24, the proportion of
subjects in the non-HU and HU treatment arms who
achieved HIV-1 RNA <50 copies/mL was not significantly
different in the ITT: M=F analysis (50% [12/24] and 47%
[14/30], respectively; P  = 0.780, Fig. 1) or the ITT:
observed analysis (57% [12/21] and 74% [14/19], respec-
tively;  P  = 0.301, Fig. 2). Differences also were not
observed at week 48, although the proportion of subjects
with HIV-1 RNA <50 copies/mL tended to be higher in the
non-HU arm in the ITT: observed analysis (82% [9/11]
and 50% [5/10], respectively; P = 0.137). No significant
differences between the treatment regimens were
observed in proportions of subjects achieving HIV-1 RNA
<400 and <50 copies/mL in the protocol-specified sub-
groups of subjects with baseline HIV-1 RNA >10,000 cop-
ies/mL or between 400–10,000 copies/mL (data not
shown). Median decrease in HIV-1 RNA from baseline
tended to be greater in the HU arm than the non-HU arm
at week 24 (-2.10 vs -1.45 log10 copies/mL, P = 0.070), but
not week 48 (-2.05 vs -2.12 log10 copies/mL, P = 0.453).
Median AAUCMB in HIV-1 RNA in the HU and non-HU
arms was not different at week 24 (-1.57 vs -1.38 log10
copies/mL, P = 0.571) or week 48 (-1.66 vs -1.41 log10
copies/mL, P = 0.585).
The time to virologic failure did not differ between the
non-HU arm and HU arm (P = 0.808, Fig. 3). In several
subjects, a time to virologic failure of 0 was observed due
to their lack of virologic response (continued or dropped
out) during the first 24 weeks. No statistically significant
difference was noted in the time to treatment failure
between the two treatment arms (P = 0.418), although the
non-HU arm demonstrated slightly longer survival time
to treatment failure than the HU arm (Fig. 4).
Immunologic response
CD4+ cell counts increased steadily and modestly over 48
weeks in the non-HU arm, whereas they decreased slightly
in the HU arm as a whole, fell markedly below baseline in
subjects who started HU at the beginning of the study, and
increased modestly between Weeks 8 and 40 in subjects
who started HU at study week 8 (Fig. 5) Median change
from baseline in CD4+ cell count in the non-HU and HU
arms was +94 cells/mm3 and -17 cells/mm3 (P = 0.028),
respectively, at week 24, and +114 cells/mm3 and -63
cells/mm3 (P = 0.007), respectively, at week 48. At week
48, the median CD4+ cell count was 403 cells/mm3 in the
non-HU arm and 249 cells/mm3 in the HU arm (P  =
0.168). The proportion of subjects achieving at least a 50-
cell increase above baseline in CD4+ cell counts was
greater in the non-HU arm at week 24 (55% vs 24%, P =
0.092) and week 48 (73% vs 18%, P = 0.030).
Safety
The number of subjects experiencing adverse events was
similar in both treatment arms. Grade 1–4 drug-related
adverse events reported by ≥  5% of subjects are presented
in Table 2. The majority of clinical adverse events were
gastrointestinal or neurological in nature and mild to
moderate in intensity. Gastrointestinal discomfort/pain,
nausea, nausea/vomiting, headache, neuropathy,
dizziness, and malaise/fatigue were reported more fre-
quently in the HU arm. The incidence of treatment-limit-
ing adverse events was also higher in the HU arm than the
non-HU arm (17 [57%] vs 5 [21%]. Events that occurred
once included nausea and vomiting (4 subjects), nausea
(3), diarrhea (2), malaise/fatigue (2), dizziness (2), head-
ache (2), allergic reaction (2), and skin rashes (2) in the
HU arm, and nausea (1), diarrhea (1), allergic reaction to
medicinal substance (1), disorders of lipid metabolism
(1), and depressive disorders (1) in the non-HU arm
(some subjects experienced more than 1 adverse event).
Serious adverse events in the non-HU and HU arms
included possible ABC-related hypersensitivity reactions
(1 and 3, respectively), appendicitis (1 each), diarrhea (1
in HU arm), bronchitis (1 in HU arm), cognitive functionBMC Infectious Diseases 2005, 5:23 http://www.biomedcentral.com/1471-2334/5/23
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disorders (1 in HU arm), pneumonia (1 in non-HU arm),
and asphyxia resulting in death (1 in non-HU arm; not
considered related to study drugs). There were no differ-
ences between the non-HU and HU arms regarding the
incidence of Grade 3 or 4 laboratory toxicities, which
included abnormalities in triglycerides (3 and 2 subjects,
respectively), amylase (1 and 2), creatine kinase (2 and 1),
alanine aminotransferase (0 and 1), and glucose (1 and
Proportion of subjects in the non-HU and HU arms who achieved plasma HIV-1 RNA <400 copies/mL and <50 copies/mL in  the intent-to-treat: missing = failure analyses Figure 1
Proportion of subjects in the non-HU and HU arms who achieved plasma HIV-1 RNA <400 copies/mL and <50 copies/mL in 
the intent-to-treat: missing = failure analyses. HU = hydroxyurea.
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0). No significant hematologic toxicities were observed.
The HU arm had only slightly lower total lymphocyte
counts (mean ± SD 27.7 ± 7.6 cells/µL vs 30.3 ± 10.3 cells/
µL) and white blood cell counts (5.4 ± 1.7 cells/µL vs 5.9
± 1.6 cells/µL) than the non-HU arm.
Discussion
In this prospective proof-of-concept clinical trial, combi-
nation therapy with ABC/EFV/ddI maintained modest
suppression of HIV-1 RNA levels and increases in CD4+
cell counts through 48 weeks of therapy in a significant
proportion of subjects who previously failed to respond to
their initial NRTI/PI-containing antiretroviral regimens.
Thus, this study showed that changing from a PI-based
regimen to an NNRTI-based regimen for virologic failure
is associated with a favorable outcome in some patients.
While cross-study comparisons are limited by differences
in subject populations, comparisons of the virologic find-
ings of NZTA4008 with those from studies in subjects
with similar baseline HIV disease characteristics and
antiretroviral experience can suggest the relative therapeu-
tic usefulness of ABC/EFV/ddI in this subject population.
Thus, ABC/EFV/ddI resulted in more subjects achieving
undetectable HIV-1 RNA levels and a more pronounced
Proportion of subjects in the non-HU and HU arms who achieved plasma HIV-1 RNA <400 copies/mL and <50 copies/mL in  the intent-to-treat: observed (B) analyses Figure 2
Proportion of subjects in the non-HU and HU arms who achieved plasma HIV-1 RNA <400 copies/mL and <50 copies/mL in 
the intent-to-treat: observed (B) analyses. HU = hydroxyurea.
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CD4+ cell count increase at 48 weeks than has been
reported with d4T/ABC/EFV/ddI in antiretroviral-experi-
enced subjects who had failed on PI-containing HAART
[24].
The addition of HU to the triple regimen did not enhance
virologic suppression with ABC/EFV/ddI over the entire
48-week study period, although in the ITT: observed anal-
ysis (but not the ITT: M = F analysis), a tendency for
greater suppression in the HU group was observed at 24
weeks (HIV-1 RNA <400 copies/mL: 89% vs 67% [non-
HU]; <50 copies/mL: 74% vs 57%; P >0.05). This trend
reversed by week 48, with a slightly higher proportion of
subjects in the non-HU arm achieving undetectable HIV-
1 RNA at that time according to both assays. In contrast,
Lafeuillade et al [24] found that when HU 500 mg twice
daily was added to an ABC/EFV/ddI/d4T regimen, the sig-
nificantly enhanced virologic suppression over ABC/EFV/
ddI/d4T alone observed at week 24 was maintained at
week 48. As HU selectively depletes a greater number of
purine, rather than pyrimidine, nucleotides in vitro [10],
theoretically greater inhibition of HIV-1 would be
expected with purine analog reverse transcriptase
inhibitors, such as ddI [25,26]. Where the effect of HU on
HAART in antiretroviral-experienced subjects has been
compared to the effect in antiretroviral-naïve subjects, a
greater HU-potentiating effect on virologic suppression
was seen in the -experienced group [21]. It is noteworthy
that not all studies of antiretroviral-experienced subjects
have shown even short-term enhancement of virologic
suppression when HU is added to HAART regimens.
Indeed, no change in virologic response was observed by
Gonzalez et al [27] in their case-control study in subjects
receiving HU-containing HAART (HU dose: 500 mg twice
daily) (n = 59) versus non-HU-containing HAART (n =
57) over a median of 18 weeks.
Subsequent to our study, Lori et al [28] showed in
RIGHT702 that HU, administered at the low dosage of
600 mg daily (lower than that in our study and most other
clinical trials), had a better efficacy and safety profile than
that seen with higher dosages. RIGHT702 was a
Time to virologic failure Figure 3
Time to virologic failure. ABC = abacavir; ddI = didanosine; EFV = efavirenz; HU = hydroxyurea. Virologic failure was defined 
by any of the following: HIV-1 RNA >400 copies/mL by week 24, repeated detection (>400 copies/mL) after initial suppression 
to undetectable levels (<400 copies/mL) or a 3-fold or greater increase in plasma HIV-1 RNA level from the nadir at week 8 or 
later.BMC Infectious Diseases 2005, 5:23 http://www.biomedcentral.com/1471-2334/5/23
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randomized, controlled clinical trial in 115 HIV-infected
patients comparing the efficacy and safety of HU at three
different daily doses (600, 800–900, or 1200 mg/day)
given as once-daily, twice-daily, or three-times-daily regi-
mens with ddI and d4T. A pairwise comparison
demonstrated a significantly greater proportion of
patients on 600 mg daily than 800–900 mg daily attaining
HIV-1 RNA <400 copies/mL at week 24 (primary end-
point) (P = 0.027) and week 48 (P = 0.03), and HIV-1
RNA <50 copies/mL at week 24 (P = 0.013) and week 48
(P = 0.028). HIV-1 RNA area under the plasma concentra-
tion-time curve (AUC) at week 24 (P = 0.016) and week
48 (P = 0.001) was also lower in the 600 mg daily groups.
The twice-daily dosing interval groups were superior to
the once-daily group for all virologic endpoints; however,
for the CD4+ count there was a tendency favoring the
once-daily dosing. The most efficacious combination of
total daily dose and dosing interval for the primary end-
point was HU 300 mg twice daily (P = 0.017). The total
daily dose groups and the dosing interval groups were
quite comparable with respect to adverse events. How-
ever, one case of lethal pancreatitis occurred in the HU
1,200 mg/day group.
Our study evaluated the effect on CD4+ count of delayed
HU treatment (until 8 weeks post-baseline) compared to
HU treatment initiated at the start of the study. HU had a
cytopenic effect on the CD4+ cell count and blunted the
CD4+ response to ABC/EFV/ddI. This effect was dimin-
ished if the addition of HU was delayed from baseline
until week 8. Rutschmann et al [22] previously compared
the effect of immediate versus delayed (by 12 weeks) addi-
tion of HU 500 mg twice daily to a HAART regimen (ddI
plus d4T), but they did not assess comparative CD4+ cell
effects. The cytopenic effect of HU on CD4+ cell counts
has been well documented in other studies of HU, espe-
cially those in which ddI was given concurrently [29].
However, a few studies have reported little or no reduc-
tion in CD4+ cell counts, or even increases [30-32]. The
cytopenic effect appears to be a dose-related rather than a
duration-related phenomenon [26]. A strategy of delaying
HU administration until several weeks after initiation of a
new HAART regimen may have potential value in the
Time to treatment failure Figure 4
Time to treatment failure. ABC = abacavir; ddI = didanosine; EFV = efavirenz; HU = hydroxyurea. Virologic failure was defined 
by any of the following: HIV-1 RNA >400 copies/mL by week 24, repeated detection (>400 copies/mL) after initial suppression 
to undetectable levels (<400 copies/mL) or a 3-fold or greater increase in plasma HIV-1 RNA level from the nadir at week 8 or 
later.BMC Infectious Diseases 2005, 5:23 http://www.biomedcentral.com/1471-2334/5/23
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treatment of HIV-infected subjects, especially those with
low CD4+ cell counts pre-treatment.
ABC/EFV/ddI was generally well tolerated, with the pri-
mary adverse events being GI in nature. The addition of
HU to this regimen did not affect the incidence of rashes,
depressive disorders, diarrhea, cognitive function disor-
ders, or possible ABC-related hypersensitivity reactions,
although its addition did increase the incidence of nausea,
nausea/vomiting, lack of appetite, headache, dizziness,
neuropathy, and malaise/fatigue. Other studies have
shown that HU at a dose of ≥ 500 mg twice daily produces
adverse GI events that may be additive to those associated
with other concurrently administered drugs [26]. In com-
bination with ddI, the incidence of peripheral neuropathy
can also be expected to rise [33]. The addition of HU 500
mg twice daily decreased the tolerability of the regimen,
with a higher proportion of subjects discontinuing due to
treatment-limiting toxicities. Other studies in which sub-
jects received HU 1000 mg/day have similarly reported a
high dropout rate due to adverse events [34,35]. Thus,
Biron et al [35] found that approximately one-quarter of
subjects receiving HU/ddI-containing antiretroviral ther-
apy discontinued treatment within 12 months. However,
unlike in our study, early withdrawal in these other stud-
ies was due primarily to hematologic toxicity (pancytope-
nia, neutropenia, anemia), elevations in amylase or liver
function tests, or pancreatitis. In contrast to other long-
term studies that evaluated HU in combination with ddI
and d4T, we did not observe a greater incidence of hema-
Median change from baseline in CD4+ cell counts in non-HU arm, total HU arm, and HU arm that began HU at baseline and at  week 8 Figure 5
Median change from baseline in CD4+ cell counts in non-HU arm, total HU arm, and HU arm that began HU at baseline and at 
week 8. BL = baseline; HU = hydroxyurea.
-150
-100
-50
0
50
100
150
0 4 8 1 62 43 24 04 8
Weeks
C
h
a
n
g
e
i
n
C
D
4
+
C
e
l
l
C
o
u
n
t
(
c
e
l
l
s
/
m
m
3
)
Non-HU Arm HU Arm HU at BL HU at Week 8BMC Infectious Diseases 2005, 5:23 http://www.biomedcentral.com/1471-2334/5/23
Page 11 of 13
(page number not for citation purposes)
tologic toxicities in the HU arm compared with the non-
HU arm. This may be due in part to the relative lack of
myelosuppression with ABC and EFV [36,37].
This study had several limitations in that it comprised a
small sample size (especially at week 48: 10 and 11 in the
HU and non-HU arms, respectively), included partici-
pants with relatively low baseline HIV-1 RNA values,
involved differing numbers of subjects in the treatment
arms, and had a high withdrawal rate. HU was rand-
omized against a combination that was highly suppres-
sive, and this could be viewed as a formidable situation in
which to verify increased efficacy. As HU was added to the
3-drug combination regimen rather than substituted for
one of the regimen components, the occurrence of addi-
tional adverse events in the HU arm compared to the non-
HU arm is not surprising. The use of non-enteric-coated
ddI in our study may have been responsible for greater
safety concerns than would have been the case had an
enteric-coated ddI formulation been given. Indeed, in an
in vitro study, Foli et al [38] showed that HU increases
mitochondrial toxicity when given with high doses of ddI.
Once-daily non-enteric-coated formulation of ddI (which
was used in the present study) results in higher maximal
Table 2: Drug-related adverse events reported by ≥  5% of subjects
Event by body system ABC/EFV/ddI (N = 24) ABC/EFV/ddI/HU (N = 30)
n (%) n (%)
Ear, nose, and throat
Nasal signs and symptoms 2 (8) 0
Endocrine and metabolic
Lack of appetite 1 (4) 3 (10)
Lipid metabolism disorders 2 (8) 2 (7)
Weight problems 0 2 (7)
Gastrointestinal
Abdominal distension 1 (4) 2 (7)
Diarrhea 5 (21) 6 (20)
Gaseous symptoms 0 2 (7)
GI discomfort and pain 0 3 (10)
Nausea 3 (13) 9 (30)
Nausea and vomiting 1 (4) 6 (20)
Musculoskeletal
Arthralgia 1 (4) 2 (7)
Neurology
Abnormal dreams 5 (21) 4 (13)
Cognitive function 2 (8) 1 (3)
disorders 2 (8) 1 (3)
Dizziness 1 (4) 4 (13)
Headache 1 (4) 5 (17)
Memory effects 0 2 (7)
Neuropathy 1 (4) 4 (13)
Sleep disorders 0 2 (7)
Non-site specific
ABC hypersensitivity 1 (4) 3 (10)
Malaise and fatigue 2 (8) 6 (20)
Psychiatric
Depressive disorders 2 (8) 1 (3)
Skin
Nail disorders 0 2 (7)
Skin rashes 3 (13) 3 (10)
Note: ABC, abacavir; ddI, didanosine; EFV, efavirenz; HU, hydroxyureaBMC Infectious Diseases 2005, 5:23 http://www.biomedcentral.com/1471-2334/5/23
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blood concentrations compared to the same doses of
enteric-coated ddI, thus making mitochondrial toxicity
more likely. Our study was also limited because it was not
powered to show significant differences between subjects
who received HU versus those who did not.
Conclusion
In conclusion, the results of this study showed that in sub-
jects who have failed initial NRTI/PI-containing regimens,
ABC/EFV/ddI may result in modest virologic suppression
and increases in CD4+ cell counts. Although no addi-
tional enhancement of virologic response was seen over
48 weeks when HU was given concurrently with ABC/
EFV/ddI, the above mentioned limitations of this study
make it difficult to make generalizable conclusions about
the ultimate value of HU in a HAART regimen. Recent
data reported for HU and ddI suggest that future efficacy/
safety studies of HU in HAART regimens should evaluate
an HU dosage no greater than 600 mg daily and use an
enteric-coated rather than a non-enteric-coated formula-
tion of ddI if the latter drug is to be administered
concurrently.
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